Unrated Danish insurer Gefion in €2m cash injection deal with shareholders

Cash injection

UK experts say cash injection is in response to growth as provider notes move was made to increase its solvency limits.

Unrated Danish insurer Gefion Insurance A/S has received a €2m (£1.74m) cash injection from its shareholders in order to improve its solvency position.

In its annual report for 2017, the provider stated: “By shareholder decision of 30 April 2018 Gefion Insurance A/S obtained commitment from its shareholders for an increase of the company’s share capital by the amount of €2m by injection of cash.”

The insurer noted that this decision improved its ratio of eligible own funds to a Solvency

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@insuranceage.co.uk.

You are currently unable to copy this content. Please contact info@insuranceage.co.uk to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Insurance Age? View our subscription options

Register

Sign up and gain access to five complimentary news articles every month.

Already have an account? Sign in here

This address will be used to create your account

Polaris at 30 – Ray Vincent

As insurance industry owned Polaris celebrates its 30th birthday, Insurance Age asks experts for their recollections on the dawn of digital trading and what is coming next.

Meet the MGA: Kayzen Specialty

Kayzen Specialty founder and CEO Charles Boorman explains to Jonathan Swift his plans for the MGA to be a go-to market for financial lines through continuous improvement across its three pillars of broker-centric, underwriter-fronted and tech-focused.

Most read articles loading...

You need to sign in to use this feature. If you don’t have an Insurance Age account, please register now.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an indvidual account here: